Comment on proposed draft Local Coverage Determinations (LCDs) on skin substitutes

London, April 26th 2024

Convatec notes the start of a forty-five day public consultation period with respect to the newly proposed draft Local Coverage Determinations (LCDs) “Skin Substitute Grafts / Cellular and Tissue-Based Products for the Treatment of Diabetic Foot Ulcers and Venous Leg Ulcers”.

As we have previously noted, the reimbursement environment in this segment is dynamic. Last year, a similar process resulted in no change in coverage. This is the beginning of a new LCD process and there is no certainty as to the timing or outcomes that may or may not result.

Convatec will actively engage with all relevant parties over the course of the consultation period. We seek an outcome that preserves choice for clinicians treating chronic wounds and is in the best interest of patients.

We are confident in the clinical efficacy of our InnovaMatrix® platform and continue to build our clinical evidence portfolio. Clinicians and patients have experienced first-hand the positive impact InnovaMatrix® products have on chronic wounds.

Contacts

Analysts & Investors	Kate Postans, Vice President of Investor Relations & Treasury	+44 (0) 7826 447807
	Sheebani Chothani, Director of Investor Relations	+44 (0) 7805 011046 ir@convatec.com
Media	Buchanan: Charles Ryland / Chris Lane	+44 (0)207 466 5000